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ABSTRACT
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Objective Chronic obstructive pulmonary disease (COPD) is a one of the major cause 
of death and disability worldwide. This study aimed to compare the quality of 
life (QOL), Activity of Daily Living (ADL), Pulmonary Function Test (PFT) 
and general health symptoms pre and after hospital-based respiratory 
physiotherapy program among COPD patients.
Methods Pre and post intervention study was conducted between January and July 
2010. A total of 54 subjects aged between 30 to 40 years old were recruited 
for this study using universal sampling method from Alzawia Teaching 
Hospital, Libya. Data collected were socio-demographic data, QOL (before 
and after the intervention) using the Short Form-36 (SF-36) questionnaire, 
ADL using the Barthel Index and the General Health Symptoms.
Results The mean SF-36 score for QOL is 30.13 (SD = 8.06) and 63.46 (SD = 13.53) 
before and after the physiotherapy respectively (with the p <0.0001). 
Patients’ Activity of Daily Living mean scores are 70.18, (SD = 16.50) and 
mean = 88.89 (SD = 13.28) before and after program (p< 0.0001). The 
general medical condition mean score after respiratory physiotherapy is 3.72 
as compared to 4.96 before the respiratory physiotherapy (p< 0.0001). 
Pulmonary Function Test shows improvement in actual/predicted FEV1 ratio 
in all 54 cases with mean improvement from 55.85 before to 81.67 after the 
pulmonary physiotherapy (with the p <0.0001).
Conclusions Hospital based respiratory physiotherapy program had significantly improved 
QOL, pulmonary function and activities of daily living among the subjects.
Keywords pulmonary function – spirometry – quality of life – activities of daily living –
respiratory physiotherapy
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is 
a major cause of death and disability worldwide. 
The Global Burden of Disease Studies1-3 found that 
COPD was the sixth commonest cause of death 
worldwide in 1990. In 2002, COPD became the 5th
leading cause of death in the world, and it is 
expected to become the 4th leading cause of death 
by the year 20304. Furthermore, COPD is
recognised as the twelfth greatest cause of chronic 
morbidity, with a predicted increase to become the 
fourth most important disability-producing illness 
by 20205. Burden of Lung Disease6 studies indicate 
a higher prevalence of COPD than previously 
anticipated. Overall, the prevalence of COPD in the 
general population is estimated to be about 1% 
across all ages, rising steeply to 8–10% or higher in 
individuals aged 40 years or older7.
COPD is a costly disease 8. In developed 
countries, exacerbations of COPD account for the 
greatest burden on the health care system. In
European Union, the total direct costs of 
respiratory disease are estimated to be about 6% of 
the total health care budget, with COPD accounting 
for 56% (Euro 38.6 billion) of this cost of 
respiratory disease9. In the United States in 2002, 
the direct costs of COPD were $18 billion and the 
indirect costs totalled $14.1 billion10.
The British Thoracic Society define 
COPD as a slowly progressive disorder 
characterized by airflow obstruction (reduced FEV1
and FEV1/FVC ratio) that does not vary markedly 
over several months of observation11 but worse 
among smokers, exposure to noxious particle or 
gases12-13. Exposure to indoor pollution or biomass 
fuel can produce identical problems; especially
cooking in poorly ventilated conditions are 
commonly affected14-16
The presence of cough and sputum 
production, whether mucoid or purulent, however 
is not a specific predictor for the subsequent 
development of COPD.17
A major step forward came with the 
epidemiological studies 18-19 showed that death and 
disability were related to progressive deterioration 
in the FEV1 (forced expiratory volume in 1 second) 
rather than persistent symptoms of cough and 
sputum production. Subsequent definitions have 
emphasized that COPD diagnosis requires the 
presence of airflow obstruction defined as a lower
than normal ratio of FEV1 to FVC (forced vital 
capacity) or vital capacity (normally <0.7)12.
Airflow obstruction in COPD arises as a 
result of narrowing, smooth-muscle hypertrophy, 
and fibrosis in the respiratory bronchioles 20,21, loss
of elastic recoil pressure due to pulmonary 
emphysema 22,23. The FEV1 reduction is mainly due 
to increase in resistance in the peripheral airways 
with a contribution from loss of elastic recoil. The 
treatment approaches fall into three broad areas: 1) 
Prevention of disease progression, 2) Management 
of stable disease, and 3) Management of 
exacerbations12. The aim of effective 
bronchodilator are now possible with negligible 
side-effects by use of long-acting inhaled [beta] 
agonist or anti-cholinergic drugs 24-29. Inhaled 
corticosteroids are still widely used in COPD, 
although the scientific basis of this approach 
remains contentious 30-31. These drugs do not 
modify the rate of decline of lung function 32-35 but 
do reduce the number of exacerbations and decline 
in health status seen in patients with more severe 
disease 36-37. Respiratory physiotherapy can be used 
at any stage of COPD and is very effective 39-45. 
Oral and nebulised corticosteroids 
accelerate the rate of improvement in lung function 
during an exacerbation, and that oral 
corticosteroids can reduce the length of the hospital 
stay49-52.
OBJECTIVE
The objective of this study is to document the 
effect of respiratory physiotherapy on a sample of 
hospitalized patients in Al-Zawia City Libya. The 
improvement in the overall conditions of the 
inpatients, after the respiratory physiotherapy are 
judged, based on the improvement in QOL score, 
improvement in symptoms, the improvement in the 
PFT results and the improvement in ADL scores. 
METHODS
This is a pre and post interventional study which 
was conducted between the period January 2010 till 
July 2010. The study was conducted at Alzawia 
Teaching Hospital from where 54 subjects were 
recruited using universal sampling method from the 
department of physiotherapy. The inclusion
criterias include Libyan, male and female above 30 
years of age with confirmed COPD diagnosis from 
respiratory physician, and referred to the 
physiotherapy department for pulmonary 
physiotherapy.
Exclusion criteria include all coronary 
heart disease patients with limited exercise 
tolerance; patients with mental disability; patients 
who are unable to complete the questionnaire;
persistent upper and lower limb injury (as the 
exercises training of respondents would include 
upper and lower limbs active movements) and 
symptoms of pain and musculoskeletal 
dysfunctions. The sample size of Kish (1965) was 
used to reach to a minimal sample of 70 samples.
Ethical approval for this study was obtained from 
the Ethical Committee of UKMMC and Alzawia 
Teaching Hospital , Libya.
There were initially as many as 81
participants, but only 54 participants completed the 
pre and post physiotherapy sessions. The response 
rate was at 62.1% with many leaving as 33 patients 
did not come for further treatment and a few 
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defaulted in-patients stay. All eligible subjects
(n=54) were given an explanation on the research 
project verbally by the researcher who is a Libyan 
trained and certified physiotherapist. Written 
consents were obtained after explanation through 
written information sheet and consent forms. The 
pulmonary function test was done by only one 
researcher in the study, thus limiting the kappa 
effect. The researcher will asess and fill in the PFT
assessment form before and after the pulmonary 
physiotherapy.
Selected subjects undertook one hour long 
physiotherapy sessions twice a week for four
weeks. Five different data collection forms were 
used to collect data. Firstly, the self administered 
questionnaire with standard SF-36 form to asses 
patient QOL. This is a quantitative scoring tool that 
uses the scores by eight domains. Secondly, the 
general health surveys form to keep track of the 
symptoms of COPD. Thirdly, PFT was measured 
via a standard spirometry machine and documented 
by the physiotherapist, using percentage data. 
Fourthly, the ADL form to assess the improvement 
before and after the pulmonary rehabilitation again 
using the scoring method. The fifth and the last 
form is to collect the respondents’ socio-
demographic profile. The first four questionnaires
was administered twice, once before the start of 
pulmonary rehabilitation and secondly upon the 
completion of four weeks after respiratory 
physiotherapy. The fifth form for the socio-
demographic data is filled only once by the patient. 
For the understanding of the questionnaire, it was 
earlier translated in Arabic language by a English 
trained Libyan academic lecturer in the hospital. 
This was later pre-tested for face validation among 
10 patients in the same hospital prior to study 
initiation.
Respiratory Physiotherapy
The regimen for respiratory physiotherapy
consisted of a warm up session for 5 minutes, 
followed by exercise training. Exercise training 
consisted of four different components; upper arm 
exercises with breathing control for 5 minutes, 
followed by another upper arm exercise with 
breathing control. Both these exercises are repeated 
three times (to a total amounting to 30 min). This is 
followed by a 10 minute brisk walk inside or 
outside circuit with in between rest as it causes 
some breathlessness. The last exercise consists of a 
10 minutes of stepping or stair climbing depending 
upon the level of tolerance.  It is followed by 5 
minutes cool down period. 
Data Analyses
The data was analyzed using SPSS version 17.0. 
Normality of the data was checked prior to the 
statistical analysis through Kolmogorov-Sminov. 
Descriptive and analytical statistical tests were 
conducted to analyze the data.  Level of 
significance was set at alpha level 0.05 and power 
at 80%. The statistical test used is the paired t-test.
RESULTS
Socio-demography: In total, 54 subjects were 
enrolled for the research. Out of these 54 subjects, 
47 % were female (n=25), whereas 53 % were male
(n=29), with mean age 45 years (SD 12.3) and 
ranged between 30-76 years. In respect to 
education status, 25.5 % had graduated, whereas 
21.2 % has no education at all.
Quality of Life: The SF-36 QOL original data was 
transformed using syntax file and the composite 
scores were then analyzed to compare QOL before 
and after the respiratory physiotherapy program. 
The result as shown in table 1, revealed that there 
was a significant difference in the scores before 
program (Mean = 30.13, SD = 8.06) and after 
program (Mean = 63.46, SD = 13.53) at t= -18.17; 
ρ <0.0001. 
Activity of Daily Living: The ADL overall score 
revealed a significant difference before program 
(Mean = 70.18, SD = 16.50) and after program 
(Mean = 88.89, SD = 13.28) with t = -7.80; ρ < 
0.0001. Table 2 shows the results of for the ADL 
scores. 
General Health Condition: For the general health 
and symptoms, they were assessed using a Health 
Condition Assessment form. The paired samples t-
test result (table 3) shows a significant decrease in 
all problem/symptom faced by patient after 
undergoing the respiratory physiotherapy program 
for one month. The overall mean score after 
respiratory physiotherapy was 3.72 as compare to 
4.96 before the respiratory physiotherapy (p value 
< 0.0001). 
Pulmonary Function Test: Results for PFT 
showed improvement in actual/predicted FEV1 
ratio in all 54 cases with mean improvement from 
55.85 from before to 81.67 after the respiratory 
physiotherapy (p value < 0.0001). The results of 
the pulmonary function test before and after the 
respiratory physiotherapy program are shown in 
table 4.
Based on all the results, it is clear that 
there is significant improvement in the clinical 
conditions as well as QOL of COPD patients after 
they have undergone respiratory physiotherapy. 
This result suggests that the respiratory 
physiotherapy program has a positive effect on the 
COPD patient health status.
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Table 1 Patients’ SF-36 Quality of Life
Total SF-36 Score Mean SD t P
Before 30.1 8.06
-18.17 <0.000
After 63.5 13.53
Table 2 Patients’ Activity of Daily Living Score
Activities Time Mean SD p
Feeding
Before 9.0 2.24 < 0.001
After 9.5 1.45
Bathing
Before 3.5 2.29 < 0.001
After 4.6 1.31
Grooming
Before 4.2 1.78 < 0.001
After 5.0 0.96
Dressing
Before 7.7 3.17 < 0.001
After 9.2 2.02
Bowels
Before 6.5 2.70 < 0.001
After 9.0 1.95
Bladder
Before 6.8 2.43 < 0.001
After 8.4 3.17
Toilet Use
Before 6.9 2.80 < 0.001
After 9.4 2.21
Transfers
Before 9.2 3.90 < 0.001
After 12.2 3.17
Mobility
Before 10.3 3.17 < 0.001
After 12.6 2.70
Stairs
Before 5.7 2.24 < 0.001
After 8.5 2.29
Overall Score
Before 70.1 16.50 < 0.001
After 88.8 13.28
Table 3 Test for the COPD symptoms before and after Physiotherapy
Symptom Time Mean SD p
Symptom 1: Dyspnea          
Before 4.4 0.56 <0.000
After 3.6 0.58
Symptom 2: Chronic Cough    
Before 4.5 0.63 <0.000
After 3.7 0.86
Symptom 3: Anxiety        
Before 4.6 0.76 <0.000
After 3.7 0.82
Symptom 4:  Fatigue 
Before 4.6 0.85 <0.000
After 3.5 0.83
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Symptom 5:  Depression
Before 4.7 0.80 <0.000
After 3.6 0.96
Symptom 6: Sputum Production    
Before 4.8 0.71 <0.000
After 3.5 0.78
Symptom 7 <0.000
Activity
Before 4.7 0.84 <0.000
After 3.7 0.81
Wellbeing
Before 4.6 0.65 <0.000
After 3.8 0.89
General feeling of 
Wellbeing? 
Before 4.6 0.76
<0.000
After 3.6 0.82
<0.000
Overall
Before 4.6 0.43
<0.000
After 3.7 0.59
a=paired t-test
Table 4 Patients Pulmonary Function Test Before and After Intervention
Pulmonary Function Test
(actual/predicted)
Time Mean SD p
FVC
Before 52.35 17.80 <0.0001
After 81.78 19.67
FEVI
Before 55.85 21.97 <0.0001
After 81.67 21.31
FEVI%
Before 56.32 22.90 <0.0001
After 80.02 23.96
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DISCUSSION
Respiratory physiotherapy is accepted non-
pharmacological intervention for individuals with 
COPD and can improve both exercise capacity and 
quality of life (QOL)53. We looked at the Medical 
Outcomes Survey Short Form 36-item 
questionnaire (SF-36), a generic QOL measures, to 
detect changes in QOL in COPD patients after of 
respiratory physiotherapy. The similar results are
shown by Lacasse et al. that the respiratory 
physiotherapy increases exercise tolerance, reduces 
symptoms, and improves health-related QOL in 
COPD patients54. These results suggest that 
respiratory physiotherapy program have a positive
effect to patient’s quality of life. The evidence base 
for this respiratory physiotherapy is well 
recognized and has been highlighted by 
professional societies 55,56 and by a recent Cochrane 
review 57. Similarly our study result also shows that 
there is a significant improvement in the QOL 
scores among the subjects after the respiratory 
physiotherapy program.
An ADL questionnaire is a scale that can 
be used to assess pulmonary disability in elderly 
patients with chronic obstructive pulmonary 
disease 58. Self-reported problems during daily 
physical activities and dependence with personal 
care assessed in 168 consecutive Dutch patients 
have documented the improvement after the 
respiratory physiotherapy 59. Moreover, respiratory 
physiotherapy have shown improvement in the 
ADL performance, improved functional status,
reduce psychological distress and enhanced quality 
of life 60. 
In our study we compared patients’ ADL
score before and after respiratory physiotherapy
program and results revealed that there is a 
significant improvement in ADL score before and 
after respiratory physiotherapy program for all 
activities. Overall score also shows a significant 
difference before and after program.
Our study illustrates how a short term 
respiratory physiotherapy program inhibits the 
progression of airflow obstruction in COPD 
patients after the 4 weeks of respiratory 
physiotherapy by increased endurance time and 
work, and improved in the general quality of live. 
We used spirometry to assessment patients 
pulmonary function before and after respiratory 
physiotherapy. Spirometric testing is used to 
confirm the diagnosis of COPD. Typical 
abnormalities include a decrease in FEV1 and a 
decrease in the ratio of FEV1 to FVC. Other 
abnormalities include an increased residual volume 
and total lung capacity, and a limited and 
incomplete response in FEV1 to bronchodilators 
(incomplete reversibility). Our study shows that
respiratory physiotherapy improved FEV1, FVC, 
with a significant difference in pulmonary function 
before and after program  for all pulmonary 
function parameters. 
Previous studies have also shown similar
improvement in FVC which may have been due to 
improved respiratory muscle function and a 
reduction in small airways disease34. FEV1 is by far 
the most frequently used index for assessing airway 
obstruction, bronchoconstriction or 
bronchodilatation; FEV1 expressed as a percentage 
of the Vital Capacity is the standard index for 
assessing and quantifying airflow limitation. The 
improvement in FEV1 in our 54 respondent cases 
was statistically significant with increased mean 
score 55.85 to 81.67; before and after respectively. 
We noted a significant inhibition of the progression 
of airways obstruction occurring after the 4 weeks 
of respiratory physiotherapy compared with FEV1
before. 
In earlier reports, regular exercise was 
noted to protect against diseases associated with 
chronic inflammation62, this inflammation is 
considered as an important element in the 
pathogenesis of COPD. The contribution of 
respiratory physiotherapy for reduction of FEV1
declined, adding an additional beneficial effect of 
respiratory physiotherapy for COPD patients. FEV1 
decline may serve as a predictor of death risk from
COPD. Therefore respiratory physiotherapy should 
be considered as a disease progress modifier as it 
enables the remaining lung tissue to regain its 
minimal functions and tolerance.
In patients with COPD, dyspnea and a 
reduced capacity for work are two of the most 
disabling symptoms experienced 63-65. In our study 
the result of comparing the health conditions before 
and after patient undergoing respiratory 
physiotherapy, yielded that there is a significant 
decrease in all COPD symptoms as dyspnea, 
chronic cough, anxiety, fatigue, depression, sputum 
production, activity and general feeling of
wellbeing which faced by patient after undergoing 
the program for one month. This result suggests 
that the program really does a positive effect to 
patient health status.
Study done by Ries et al. showed the
definite benefits of an hospital and home-based
comprehensive respiratory physiotherapy program 
in symptom of patients with COPD as compared 
with patients who received only routine of therapy, 
such as optimisation of medication66.
Study Limitation
The study is very dependent on agreaable 
respondents that have the potential to improperly 
exhale and inhale for the spirometry tests. The 
patients participation are also compromised due to 
the exercises done during physiotherapy that limit 
coorperation and full participations in the 4 weeks 
program. Patients that are on other types of 
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medication may synergistically enhance the effects 
of therapy, providing biased results.
CONCLUSION
We are able to demonstrate that our inpatient 
research samples that respiratory physiotherapy
improved outcomes after it is administered to the 
inpatients with COPD. Clinically relevant 
improvement, evident by the improvement in 
pulmonary function tests and health outcomes in 
term of QOL measurements are demonstrated. 
With these results we would like to advocate that 
respiratory physiotherapy programs should be set 
up and implemented in all the inpatient facilities
and lower level of resources. Libya, a developing 
country with conservative society, needed more 
explanatory data and researches to persuade a 
policy change that lead to early COPD detections
and the set-ups of mitigating strategies such as
COPD rehabilitation programs. Such program can 
improve patient’s pulmonary function, patient’s 
quality of life and can make a significant difference 
in activity of daily living score for all activities.
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